Table 3 ATRX status prediction using presence and absence of TP53 and IDH mutations compared to ARTX immunohistochemistry and the FoundationOne targeted next-generation sequencing panel
Infiltrating glioma subgroup | Prediction compared to IHC | Prediction compared to foundation medicine |
|---|---|---|
Oligodendroglioma | 13/13 (100%) | 3/3 (100%) |
IDH-mutant Infiltrating Astrocytoma | 12/22 (55%) | 9/12–12/12 (75–100%) |
IDH-wild type Infiltrating Astrocytoma, presenting in adults | 102/102 (100%) | 57/63 – 60/63 (91- 95%) |